Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors
27 6월 2024 - 8:00PM
Business Wire
Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”),
a clinical-stage biotechnology company developing a new generation
of targeted antitumor virotherapies, today announced the
appointment of Dr. George E. Peoples, MD, FACS, to the company’s
Board of Directors, effective July 1, 2024.
“Dr. Peoples is a highly esteemed figure in the field of cancer
immunotherapy, bringing decades of experience in cancer vaccine
development and clinical research to our Board,” said Allan
Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics.
“Dr. Peoples’ pioneering work in cancer immunotherapy and his
extensive experience in both clinical and military settings will be
invaluable as we advance our portfolio of cancer immunotherapies
into later-stage clinical trials.”
Dr. Peoples is the Founder and Director of the Cancer Vaccine
Development Program (CVDP), with over 20 years of experience in
discovering, developing, and clinically testing cancer vaccines,
four of which have been licensed for commercial development. He
also founded LumaBridge (formerly Cancer Insight), an
oncology-focused Contract Research Organization (CRO) and
development partner currently engaged with over 25 pre-clinical and
clinical trial sponsors.
In addition to his roles at CVDP and LumaBridge, Dr. Peoples
serves as a Professor of Surgery at the Uniformed Services
University of the Health Sciences (USUHS) and an adjunct Professor
of Surgical Oncology at MD Anderson Cancer Center. He has held
significant positions such as Chair of the Cancer Care Program at
San Antonio Military Medical Center and Military Director of the
United States Military Cancer Institute. Dr. Peoples is a graduate
of the United States Military Academy at West Point and the Johns
Hopkins School of Medicine, and he completed his surgical training
at Harvard’s Brigham and Women’s Hospital and a surgical oncology
fellowship at MD Anderson Cancer Center. He has authored over 350
peer-reviewed manuscripts, abstracts, and book chapters.
“Calidi Biotherapeutics has made remarkable strides in the
development of allogeneic stem cell therapies and oncolytic virus
delivery systems,” said Dr. Peoples. “I am excited to join the
Board and contribute to the company’s innovative approach to cancer
treatment. I look forward to working with the Calidi team to
advance these promising therapies through clinical development and
towards commercialization.”
About Calidi Biotherapeutics:
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage
immuno-oncology company with proprietary technology designed to arm
the immune system to fight cancer. Calidi’s novel stem cell-based
platforms are utilizing potent allogeneic stem cells capable of
carrying payloads of oncolytic viruses for use in multiple oncology
indications, including high-grade gliomas and solid tumors.
Calidi’s clinical stage off-the-shelf, universal cell-based
delivery platforms are designed to protect, amplify, and potentiate
oncolytic viruses leading to enhanced efficacy and improved patient
safety. Calidi’s preclinical off-the-shelf enveloped virotherapies
are designed to target disseminated solid tumors. This dual
approach can potentially treat, or even prevent, metastatic
disease. Calidi Biotherapeutics is headquartered in San Diego,
California. For more information, please visit
www.calidibio.com.
Forward-Looking Statements
This press release may contain forward-looking statements for
purposes of the “safe harbor” provisions under the United States
Private Securities Litigation Reform Act of 1995. Terms such as
“anticipates,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intends,” “may,” “might,” “plan,” “possible,”
“potential,” “predicts,” “project,” “should,” “towards,” “would” as
well as similar terms, are forward-looking in nature, but the
absence of these words does not mean that a statement is not
forward-looking. These forward-looking statements include, but are
not limited to, statements concerning upcoming key milestones
(including the reporting of interim clinical results and the dosing
of patients), planned clinical trials, and statements relating to
the safety and efficacy of Calidi’s therapeutic candidates in
development. Any forward-looking statements contained in this
discussion are based on Calidi’s current expectations and beliefs
concerning future developments and their potential effects and are
subject to multiple risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth or
implied in such forward-looking statements. These risks and
uncertainties include, but are not limited to, the risk that Calidi
is not able to raise sufficient capital to support its current and
anticipated clinical trials, the risk that early results of
clinical trials do not necessarily predict final results and that
one or more of the clinical outcomes may materially change
following more comprehensive review of the data, and as more
patient data becomes available, the risk that Calidi may not
receive FDA approval for some or all of its therapeutic candidates.
Other risks and uncertainties are set forth in the section entitled
“Risk Factors” and “Cautionary Note Regarding Forward-Looking
Statements” in the Company’s Registration Statements filed with the
SEC on Form S-4 filed on August 2, 2023, on Form S-1 filed on
October 6, 2023, on Form S-1 filed on January 29, 2024, as amended
on February 7, 2024, on Form 10-K filed on March 15, 2024, and
Final Prospectus filed on April 17, 2024.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240627634366/en/
For Investors and Media: Stephen
Thesing IR@Calidibio.com
Calidi Biotherapeutics (AMEX:CLDI)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Calidi Biotherapeutics (AMEX:CLDI)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024